Global Trust Asset Management LLC Raises Stock Holdings in Johnson & Johnson (NYSE:JNJ)


Share on StockTwits

Global Trust Asset Management LLC lifted its holdings in Johnson & Johnson (NYSE:JNJ) by 34.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 7,386 shares of the company’s stock after buying an additional 1,882 shares during the quarter. Global Trust Asset Management LLC’s holdings in Johnson & Johnson were worth $1,162,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of JNJ. Natixis boosted its position in Johnson & Johnson by 298.8% during the 3rd quarter. Natixis now owns 1,761,993 shares of the company’s stock valued at $262,326,000 after acquiring an additional 1,320,224 shares in the last quarter. Voloridge Investment Management LLC boosted its position in Johnson & Johnson by 167.3% during the 3rd quarter. Voloridge Investment Management LLC now owns 1,854,450 shares of the company’s stock valued at $276,091,000 after acquiring an additional 1,160,773 shares in the last quarter. Polar Capital LLP boosted its position in Johnson & Johnson by 657.6% during the 3rd quarter. Polar Capital LLP now owns 1,207,177 shares of the company’s stock valued at $179,725,000 after acquiring an additional 1,047,825 shares in the last quarter. Boston Partners boosted its position in Johnson & Johnson by 16.1% during the 3rd quarter. Boston Partners now owns 6,862,037 shares of the company’s stock valued at $1,021,620,000 after acquiring an additional 949,327 shares in the last quarter. Finally, Morgan Stanley boosted its position in Johnson & Johnson by 4.3% during the 3rd quarter. Morgan Stanley now owns 22,472,765 shares of the company’s stock valued at $3,345,745,000 after acquiring an additional 933,976 shares in the last quarter. Hedge funds and other institutional investors own 61.26% of the company’s stock.

Shares of NYSE JNJ traded down $0.62 during trading on Wednesday, reaching $157.51. 151,268 shares of the company traded hands, compared to its average volume of 8,505,344. The firm’s fifty day simple moving average is $152.58 and its 200 day simple moving average is $148.21. The stock has a market cap of $414.65 billion, a P/E ratio of 24.86, a PEG ratio of 3.30 and a beta of 0.68. Johnson & Johnson has a 12-month low of $109.16 and a 12-month high of $161.32. The company has a current ratio of 1.48, a quick ratio of 1.24 and a debt-to-equity ratio of 0.51.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Sunday, October 18th. The company reported $2.20 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.98 by $0.22. The business had revenue of $21.08 billion during the quarter, compared to analyst estimates of $20.15 billion. Johnson & Johnson had a return on equity of 34.64% and a net margin of 21.01%. The company’s revenue was up 1.7% on a year-over-year basis. During the same quarter last year, the business posted $2.12 EPS. As a group, research analysts expect that Johnson & Johnson will post 7.99 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 9th. Shareholders of record on Tuesday, February 23rd will be paid a dividend of $1.01 per share. The ex-dividend date of this dividend is Monday, February 22nd. This represents a $4.04 dividend on an annualized basis and a dividend yield of 2.56%. Johnson & Johnson’s payout ratio is currently 46.54%.

In related news, COO Michael E. Sneed sold 54,662 shares of Johnson & Johnson stock in a transaction dated Wednesday, December 9th. The stock was sold at an average price of $152.93, for a total value of $8,359,459.66. Following the completion of the transaction, the chief operating officer now owns 110,741 shares in the company, valued at approximately $16,935,621.13. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 0.27% of the company’s stock.

A number of analysts have recently weighed in on JNJ shares. Raymond James reissued a “buy” rating on shares of Johnson & Johnson in a research report on Friday, November 20th. Credit Suisse Group raised their price objective on Johnson & Johnson from $163.00 to $168.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 14th. Morgan Stanley raised their price objective on Johnson & Johnson from $170.00 to $178.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 15th. BidaskClub raised Johnson & Johnson from a “strong sell” rating to a “sell” rating in a research report on Wednesday, January 6th. Finally, Cantor Fitzgerald raised their price objective on Johnson & Johnson from $168.00 to $180.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 14th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and ten have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $165.50.

About Johnson & Johnson

Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Story: What is the yield curve?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.